Fortrea Holdings (FTRE) Change in Account Payables (2022 - 2026)
Fortrea Holdings (FTRE) reported Change in Account Payables of $41.3 million for Q1 2026, up 245.42% on a YoY basis from $12.0 million in Q1 2025, and up 304.46% quarter-over-quarter from -$20.2 million in Q4 2025.
Fortrea Holdings (FTRE) Change in Account Payables (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Change in Account Payables for 5 years, with the latest figure at $41.3 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 245.42% year-over-year to $41.3 million; the trailing twelve-month figure through Mar 2026 stood at -$40.2 million (down 98.03% YoY), and the FY2025 full-year result was -$109.9 million, down 1626.39% from the prior year.
- Change in Account Payables for Q1 2026 stood at $41.3 million, up from -$20.2 million in the prior quarter.
- The five-year high for Change in Account Payables was $41.3 million in Q1 2026, with the low at -$42.9 million in Q3 2025.
- Historically, Change in Account Payables has averaged -$120000.0 across 5 years, with a median of $1.3 million in 2022.
- Annual changes were most pronounced in 2024 — Change in Account Payables soared 2880.0% — and 2025, when it sank 3055.56%.
- Fortrea Holdings' Change in Account Payables stood at $1.3 million in 2022, then soared by 623.08% to $9.4 million in 2023, then slumped by 85.11% to $1.4 million in 2024, then plunged by 1542.86% to -$20.2 million in 2025, then soared by 304.46% to $41.3 million in 2026.
- The last three Change in Account Payables figures came in at $41.3 million (Q1 2026), -$20.2 million (Q4 2025), and -$42.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 41.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.30 Mn |
| Mar 31, 2026 | 41.30 Mn |
| Dec 31, 2025 | -20.20 Mn |
| Dec 31, 2025 | -20.20 Mn |
| Sep 30, 2025 | -42.90 Mn |
| Sep 30, 2025 | -42.90 Mn |
| Jun 30, 2025 | -18.40 Mn |
| Jun 30, 2025 | -18.40 Mn |
| Mar 31, 2025 | -28.40 Mn |
| Mar 31, 2025 | -28.40 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | -7.20 Mn |
| Sep 30, 2024 | -7.20 Mn |
| Jun 30, 2024 | 13.90 Mn |
| Jun 30, 2024 | 13.90 Mn |
| Mar 31, 2024 | -900,000.00 |
| Mar 31, 2024 | -900,000.00 |
| Dec 31, 2023 | 9.40 Mn |
| Dec 31, 2023 | 9.40 Mn |